MA54948A - Dérivés thiéno[3,2-b]-pyrrole[3,2-d]pyridazinones et leur utilisation comme dérivés de pkm2 pour le traitement de troubles associés au cancer, à l'obésité et au diabète - Google Patents
Dérivés thiéno[3,2-b]-pyrrole[3,2-d]pyridazinones et leur utilisation comme dérivés de pkm2 pour le traitement de troubles associés au cancer, à l'obésité et au diabèteInfo
- Publication number
- MA54948A MA54948A MA054948A MA54948A MA54948A MA 54948 A MA54948 A MA 54948A MA 054948 A MA054948 A MA 054948A MA 54948 A MA54948 A MA 54948A MA 54948 A MA54948 A MA 54948A
- Authority
- MA
- Morocco
- Prior art keywords
- derivatives
- pkm2
- thieno
- pyrrole
- obesity
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/14—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962805040P | 2019-02-13 | 2019-02-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA54948A true MA54948A (fr) | 2021-12-22 |
Family
ID=69941460
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA054948A MA54948A (fr) | 2019-02-13 | 2020-02-12 | Dérivés thiéno[3,2-b]-pyrrole[3,2-d]pyridazinones et leur utilisation comme dérivés de pkm2 pour le traitement de troubles associés au cancer, à l'obésité et au diabète |
Country Status (14)
Country | Link |
---|---|
US (1) | US20220127267A1 (fr) |
EP (1) | EP3924056A1 (fr) |
JP (1) | JP2022520090A (fr) |
KR (1) | KR20210128435A (fr) |
CN (1) | CN113646050A (fr) |
AU (1) | AU2020221837A1 (fr) |
BR (1) | BR112021015996A2 (fr) |
CA (1) | CA3129829A1 (fr) |
CO (1) | CO2021011919A2 (fr) |
IL (1) | IL285445A (fr) |
MA (1) | MA54948A (fr) |
MX (1) | MX2021009743A (fr) |
SG (1) | SG11202108744WA (fr) |
WO (1) | WO2020167976A1 (fr) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11364240B2 (en) | 2017-08-15 | 2022-06-21 | Agios Pharmaceuticals, Inc. | Pyruvate kinase activators for use in treating blood disorders |
CA3183980A1 (fr) * | 2020-07-21 | 2022-01-27 | The Regents Of The University Of Michigan | Compositions et procedes d'activation de la pyruvate kinase |
WO2022170200A1 (fr) | 2021-02-08 | 2022-08-11 | Global Blood Therapeutics, Inc. | Dérivés de 1-(2-sulfonyl-2,6-dihydropyrrolo[3,4-c]pyrazol-5-yl]-éthanone servant d'activateurs de pyruvate kinase (pkr) et de pkm2 pour le traitement de la drépanocytose |
CA3231728A1 (fr) | 2021-09-30 | 2023-04-06 | Sitryx Therapeutics Limited | Nouveaux composes |
WO2023079294A1 (fr) | 2021-11-05 | 2023-05-11 | Sitryx Therapeutics Limited | Dérivés de phtalazine utilisés comme modulateurs de la pyruvate kinase |
CN118434720A (zh) | 2021-12-22 | 2024-08-02 | 西特瑞治疗有限公司 | 作为丙酮酸激酶调节剂的酞嗪衍生物 |
MX2024007744A (es) | 2021-12-22 | 2024-07-01 | Sitryx Therapeutics Ltd | Derivados de ftalazina como moduladores de piruvato quinasa. |
CN115487190A (zh) * | 2022-11-01 | 2022-12-20 | 复旦大学附属中山医院 | 丙酮酸激酶m2激活剂在制备治疗系统性红斑狼疮的药物中的应用 |
CN116808223A (zh) * | 2023-08-04 | 2023-09-29 | 复旦大学附属中山医院 | 丙酮酸激酶m2激活剂在制备治疗银屑病的药物中的应用 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3173415B1 (fr) * | 2008-10-09 | 2019-06-05 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Activateurs de la pyruvate kinase humaine |
US8785450B2 (en) | 2009-06-29 | 2014-07-22 | Agios Pharmaceuticals, Inc. | Therapeutic compounds and compositions |
EP2704719B1 (fr) * | 2011-05-03 | 2018-02-21 | Agios Pharmaceuticals, Inc. | Activateurs de pyruvate kinase destinés à être utilisés pour allonger la durée de vie des érythrocytes et traiter l'anémie |
CA2834692A1 (fr) * | 2011-05-03 | 2012-11-08 | Agios Pharmaceuticals, Inc. | Activateurs de la pyruvate kinase destines a une utilisation therapeutique |
PL3406251T3 (pl) | 2011-05-03 | 2024-04-29 | Agios Pharmaceuticals, Inc. | Aktywatory kinazy pirogronianowej do stosowania w terapii |
US9921221B2 (en) | 2012-07-26 | 2018-03-20 | Joslin Diabetes Center, Inc. | Predicting and treating diabetic complications |
US11364240B2 (en) * | 2017-08-15 | 2022-06-21 | Agios Pharmaceuticals, Inc. | Pyruvate kinase activators for use in treating blood disorders |
-
2020
- 2020-02-12 SG SG11202108744WA patent/SG11202108744WA/en unknown
- 2020-02-12 AU AU2020221837A patent/AU2020221837A1/en not_active Abandoned
- 2020-02-12 JP JP2021547190A patent/JP2022520090A/ja not_active Withdrawn
- 2020-02-12 BR BR112021015996A patent/BR112021015996A2/pt not_active IP Right Cessation
- 2020-02-12 MX MX2021009743A patent/MX2021009743A/es unknown
- 2020-02-12 KR KR1020217029380A patent/KR20210128435A/ko not_active Application Discontinuation
- 2020-02-12 CN CN202080027241.9A patent/CN113646050A/zh active Pending
- 2020-02-12 CA CA3129829A patent/CA3129829A1/fr active Pending
- 2020-02-12 US US17/429,073 patent/US20220127267A1/en active Pending
- 2020-02-12 WO PCT/US2020/017965 patent/WO2020167976A1/fr unknown
- 2020-02-12 MA MA054948A patent/MA54948A/fr unknown
- 2020-02-12 EP EP20713430.5A patent/EP3924056A1/fr not_active Withdrawn
-
2021
- 2021-08-08 IL IL285445A patent/IL285445A/en unknown
- 2021-09-10 CO CONC2021/0011919A patent/CO2021011919A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
MX2021009743A (es) | 2021-11-12 |
BR112021015996A2 (pt) | 2021-11-09 |
EP3924056A1 (fr) | 2021-12-22 |
CO2021011919A2 (es) | 2021-12-10 |
KR20210128435A (ko) | 2021-10-26 |
CA3129829A1 (fr) | 2020-08-20 |
SG11202108744WA (en) | 2021-09-29 |
JP2022520090A (ja) | 2022-03-28 |
WO2020167976A1 (fr) | 2020-08-20 |
CN113646050A (zh) | 2021-11-12 |
AU2020221837A1 (en) | 2021-09-02 |
US20220127267A1 (en) | 2022-04-28 |
IL285445A (en) | 2021-09-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA54948A (fr) | Dérivés thiéno[3,2-b]-pyrrole[3,2-d]pyridazinones et leur utilisation comme dérivés de pkm2 pour le traitement de troubles associés au cancer, à l'obésité et au diabète | |
MA51520A (fr) | Dérivés de 1,3,4,5-tétrahydro-2h-pyrido[4,3-b]indole pour le traitement, le soulagement ou la prévention de troubles associés à des agrégats de tau comme la maladie d'alzheimer | |
WO2008063202A3 (fr) | Composés hétérobicycliques de thiophène et leurs méthodes d'utilisation | |
MA56387A (fr) | Dérivés de quinazoline-4-one utiles pour le traitement de maladies et de troubles associés à braf | |
MA28481B1 (fr) | Dérivés d'imidazole pour le traitement de troubles neurodégénératifs | |
MA51568A (fr) | Composés aza-, oxa et thia-pregnan-20-one-3.alpha.-ol s'utilisant dans le traitement de troubles du système nerveux central | |
WO2006015060A3 (fr) | Composes isoindoline et methodes d'utilisation de ces derniers | |
GEP20207149B (en) | Allosteric modulators of nicotinic acetylcholine receptors | |
EP3037421A3 (fr) | Inhibiteurs de mlk et procédés d'utilisation | |
EA201000016A1 (ru) | Способы и композиции для лечения рака, опухолей и нарушений, связанных с опухолями | |
WO2009117277A3 (fr) | Combinaisons de conjugués anticorps anti-her2-médicament et d’agents chimiothérapiques, et procédés d’utilisation | |
MA28871B1 (fr) | Derives tricycliques accoles pour le traitement de troubles psychotiques | |
MA52747A (fr) | Composés tétrahydro-1h-pyrazino[2,1-ajisoindolylquinoline pour le traitement d'une maladie auto-immune | |
MX2020009668A (es) | Métodos novedosos. | |
MA32506B1 (fr) | Nouveaux composes | |
EA201390712A1 (ru) | Производные пиридазина, композиции и способы лечения когнитивного нарушения | |
MA28583B1 (fr) | Dérivés de pyrimidine pour le traitement d'une croissance cellulaire anormale | |
JO3789B1 (ar) | التراكيب والوسائل العلاجية المعتمدة لمعالجة الامراض المتعلقة بالمتممة | |
EA201390710A1 (ru) | Производные бензодиазепина, композиции и способы для лечения когнитивного нарушения | |
IL255782A (en) | Pharmacotherapeutic agents of levatiracetam with prolonged release | |
MA31798B1 (fr) | Composés organiques | |
MA55594A (fr) | Composés hexahydro-1h-pyrazino[1,2-a]pyrazine pour le traitement d'une maladie auto-immune | |
EA202190431A1 (ru) | Гетероароматические модуляторы nmda рецептора и их применение | |
WO2014194242A3 (fr) | Inhibiteurs de flt3 et leurs utilisations | |
MX2020008523A (es) | Compuesto que tiene actividad agonista del receptor esfingosina-1-fosfato [(2s,3r,4e)-2-amino-3-hidroxioctadec-4-enil- 1-fosfato (s1p5). |